Oncological miR-182-3p, a Novel Smooth Muscle Cell Phenotype Modulator, Evidences From Model Rats and Patients
Authors:
- Lan SunLan Sun
- Yongyi BaiYBYongyi Bai
- Rui ZhaoRZRui Zhao
- Tao SunTSTao Sun
- Ruihua CaoRCRuihua Cao
- Fuyu WangFWFuyu Wang
- Guorong HeGHGuorong He
- Wen ZhangWZWen Zhang
- Ying ChenYCYing Chen
- Ping YePYPing Ye
- Guanhua DuGDGuanhua Du
- 1 July 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 36 (7) , 1386-1397
Abstract
Objective—: Vascular smooth muscle cell (VSMC) phenotype change is a hallmark of vascular remodeling, which contributes to atherosclerotic diseases and can be regulated via microRNA-dependent mechanisms. We recently identified that asymmetrical dimethylarginine positively correlates to vascular remodeling–based diseases. We hypothesized that asymmetrical dimethylarginine induces smooth muscle cell (SMC) phenotypic change via a microRNA-dependent mechanism. Approach and Results—: Microarray analysis enabled the identification of downregulation of miR-182-3p in asymmetrical dimethylarginine–treated human aortic artery SMCs. The myeloid-associated differentiation marker (MYADM) was identified as the downstream target of miR-182-3p and implicated to contribute to miR-182-3p knockdown–mediated SMC phenotype change, which was evidenced by the increased proliferation and migration and reduced expression levels of phenotype-related genes in human aortic artery SMCs through the ERK/MAP (extracellular signal-regulated kinase/mitogen-activated protein) kinase–dependent mechanism. When inhibiting MYADM in the presence of miR-182-3p inhibitor or overexpressing MYADM in the presence of pre-miR-182-3p, human aortic artery SMCs were reversed to the differentiation phenotype. In vivo, adeno-miR-182-3p markedly suppressed carotid neointimal formation by using balloon-injured rat carotid artery model, specifically via decreased MYADM expression, whereas adeno-miR-182-3p inhibitor significantly promoted neointimal formation. Atherosclerotic lesions from patients with high asymmetrical dimethylarginine plasma levels exhibited decreased miR-182-3p expression levels and elevated MYADM expression levels. Conclusions—: miR-182-3p is a novel SMC phenotypic modulator by targeting MYADM .Keywords
This publication has 20 references indexed in Scilit:
- BubR1 Insufficiency Inhibits Neointimal Hyperplasia Through Impaired Vascular Smooth Muscle Cell Proliferation in MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2015
- MicroRNA-663 Regulates Human Vascular Smooth Muscle Cell Phenotypic Switch and Vascular Neointimal FormationCirculation Research, 2013
- Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissuesGene, 2013
- Inhibition of Proliferation and Induction of Autophagy by Atorvastatin in PC3 Prostate Cancer Cells Correlate with Downregulation of Bcl2 and Upregulation of miR-182 and p21PLOS ONE, 2013
- Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)International Journal of Molecular Medicine, 2013
- Association of circulating levels of asymmetric dimethylarginine (ADMA) with carotid intima-media thickness: Evidence from 6168 participantsAgeing Research Reviews, 2013
- Asymmetric dimethylarginine confers the communication between endothelial and smooth muscle cells and leads to VSMC migration through p38 and ERK1/2 signaling cascadeFEBS Letters, 2011
- Efficient in vivo microRNA targeting of liver metastasisOncogene, 2010
- Role of Asymmetric Dimethylarginine in Vascular Injury in Transgenic Mice Overexpressing Dimethylarginie Dimethylaminohydrolase 2Circulation Research, 2007
- miRBase: microRNA sequences, targets and gene nomenclatureNucleic Acids Research, 2006